From: Synergy in monoclonal antibody neutralization of HIV-1 pseudoviruses and infectious molecular clones
 | PSEUDOVIRUS | T/F IMC | Average | ||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
 | Combination index | ||||||||||||
 | SF162 | AC10. 0.29 | REJO 4551.67 | RHPA 4259.7 | THRO 4156.18 | REJO.c | RHPA.c | THRO.c | CH040.c | CH058.c | CH077.t | Pseudo | T/F |
4E10 + 2F5 | 1.87* ± 0.59 | 0.79*** ± 0.17 | 1.12** ± 0.29 | 0.38 ± 0.11 | - | 1.76* ± 0.44 | - | - | 0.41 ± 0.3 | - | - | 1.04 | 1.08 |
4E10 + b12 | 0.32 ± 0.18 | 0.84*** ± 0.21 | 0.64 ± 0.13 | 0.18 ± 0.07 | 0.87*** ± 0.21 | - | - | 0.6 ± 0.17 | 0.016 ± 0.018 | - | - | 0.57 | 0.3 |
4E10 + 2G12 | 0.6 ± 0.25 | - | - | - | - | - | - | - | - | - | - | 0.6 | n.d. |
4E10 + PG9 | - | 0.455 ± 0.16 | 0.85*** ± 0.15 | - | - | 0.41 ± 0.07 | - | - | - | - | - | 0.65 | 0.41 |
4E10 + PG16 | - | 0.25 ± 0.14 | 0.61 ± 0.16 | 0.2 ± 0.07 | - | 0.35 ± 0.17 | - | - | - | - | - | 0.35 | 0.35 |
2F5 + b12 | 0.68*** ± 0.37 | 0.91** ± 0.19 | 0.58 ± 0.13 | 0.27 ± 0.09 | - | - | - | - | 0.36 ± 0.16 | 0.43 ± 0.15 | - | 0.61 | 0.39 |
2F5 + 2G12 | 0.82*** ± 0.49 | - | - | - | - | - | - | - | - | 0.31 ± 0.19 | - | 0.82 | 0.31 |
2F5 + PG9 | - | 0.54 ± 0.13 | 0.91** ± 0.2 | - | - | 0.66 ± 0.16 | - | - | - | - | - | 0.72 | 0.66 |
2F5 + PG16 | - | 0.22 ± 0.05 | 0.78*** ± 0.23 | 0.34 ± 0.09 | - | 0.38 ± 0.1 | - | - | - | - | - | 0.44 | 0.38 |
b12 + 2G12 | 0.72*** ± 0.72 | - | - | - | - | - | - | - | - | 0.48 ± 0.14 | - | 0.72 | 0.48 |
b12 + PG9 | - | 0.68 ± 0.2 | 1.02** ± 0.39 | - | - | - | - | - | - | - | 0.48 ± 0.14 | 0.85 | 0.48 |
b12 + PG16 | - | 0.29 ± 0.21 | 0.72 ± 0.09 | 0.31 ± 0.17 | - | - | 0.8*** ± 0.18 | - | - | - | 0.61*** ± 0.32 | 0.44 | 0.66 |
2G12 + PG9 | - | - | - | - | - | - | - | - | - | - | - | n.d | n.d |
2G12 + PG16 | - | - | - | - | - | - | - | - | - | - | - | n.d | n.d |
PG9 + PG16 | - | 0.38 ± 0.11 | 2.92* ± 0.54 | - | - | 0.93** ± 0.18 | - | - | - | - | 0.72*** ± 0.36 | 1.65 | 0.82 |